AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34922061
Drug: Anthocyanins (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanins (320 mg daily for 12 weeks)
Trial: 34127089
Drug: Lurasidone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone monotherapy 20-60 mg/d
Trial: 34127089
Drug: Lurasidone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone monotherapy 80-120 mg/d
Trial: 34127089
Drug: Lurasidone adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone adjunctive therapy 20-120 mg/d + Li/VPA
Trial: 34127089
Drug: Lurasidone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone monotherapy (long-term)
Trial: 34127089
Drug: Adjunctive lurasidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive lurasidone therapy (long-term)
Trial: 34127089
Drug: Lurasidone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone monotherapy (pediatric)
Trial: 35847029
Drug: Jinzhen Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinzhen Oral Liquid (JZOL) and Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution (AHCHOS) placebo
Trial: 32963028
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy (dexamethasone)
Trial: 36469833
Drug: R-DHAP (rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-DHAP (rituximab plus dexamethasone, high-dose cytarabine, and cisplatin)
Trial: 32718308
Drug: Pharmacotherapy for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy for reduction in drinking
Trial: 33931884
Drug: Losmapimod 15
RxNorm normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod 15 mg (Part B)
Trial: 33931884
Drug: Losmapimod 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod 7.5 mg (Part B)
Trial: 33931884
Drug: Losmapimod 15
RxNorm normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod 15 mg (Part C)
Trial: 32381158
Drug: Achieved LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achieved LDL-C <20 mg/dl
Trial: 32381158
Drug: Achieved LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achieved LDL-C ≥100 mg/dl
Trial: 35976578
Drug: NOL-guided fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NOL-guided fentanyl dosing (NOL)
Trial: 33881715
Drug: YYHG high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYHG high-dose
Trial: 33881715
Drug: YYHG low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: YYHG low-dose
Trial: 33881715
Drug: YYHG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYHG treatment
Trial: 32207836
Drug: Oral naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naloxone co-administration with ticagrelor and morphine
Trial: 35141806
Drug: L-PRF +
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRF + DPSC
Trial: 32228267
Drug: Risk score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk score based on age >52, WBC >10 × 10^9/L, PLT ≤10 × 10^9/L, LDH >500 U/L
Trial: 34324700
Drug: Fremanezumab monthly
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8)
Trial: 34324700
Drug: Fremanezumab quarterly
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab quarterly (675 mg at baseline and placebo at weeks 4 and 8)
Trial: 34808749
Drug: Radial shock
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shock wave therapy (RSWT) in the lateral elbow area plus scapular back area
Trial: 34808749
Drug: Radial shock
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shock wave therapy (RSWT) only in the lateral elbow area
Trial: 35172198
Drug: Canagliflozin 100mg
RxNorm normalized name: CANAGLIFLOZIN 100MG TAB
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Canagliflozin 100mg daily
Trial: 32275362
Drug: Itopride hydrochloride
RxNorm normalized name: Itopride hydrochloride
DrugBank: Itopride (DB04924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride hydrochloride tablets, 50 mg each time, three times a day for 6 weeks
Trial: 34496174
Drug: Iron syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron syrup
Trial: 34496174
Drug: Iron syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron syrup and multiple micronutrient powders
Trial: 34496174
Drug: Iron syrup,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron syrup, multiple micronutrient powders, and placebo
Trial: 36104745
Drug: Pregabalin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (75 mg twice per day) + placebo
Trial: 36104745
Drug: Pregabalin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (75 mg twice per day) + agomelatine (25 mg per night)
Trial: 32029262
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 0.5 μg kg‐1
Trial: 32029262
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 1.0 μg kg‐1
Trial: 32029262
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 1.5 μg kg‐1
Trial: 32029262
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 2.0 μg kg‐1
Trial: 32029262
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (all doses)
Trial: 36270561
Drug: Nefecon (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefecon (16 mg/d)
Trial: 36343893
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg mocravimod/day
Trial: 36343893
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg mocravimod/day
Trial: 35306633
Drug: Intensive education
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive education intervention (IG) with repeated, structured multimodal education on correct injection techniques.
Trial: 36007870
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (CP) therapy (300mL)
Trial: 33683643
Drug: Energy Healing
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy Healing (EH) therapy with three sessions
Trial: 33683643
Drug: Energy Healing
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy Healing (EH) therapy
Trial: 37847695
Drug: Medication Review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Review with Follow-up (MRF) service
Trial: 34677609
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current brain stimulation (tDCS; 2 mA) for 20 minutes before chemotherapy
Trial: 36701604
Drug: Intravenous meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meperidine
Trial: 35354637
Drug: BP self-monitoring
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BP self-monitoring and tele-monitoring plus a free SPC-based telemedicine titration therapy for 6 months
Trial: 35354637
Drug: Self-monitoring BP
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-monitoring BP without any therapy change
Trial: 35175066
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose alcohol condition (BrAC = .04%)
Trial: 35175066
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose alcohol condition (BrAC = .08%)
Trial: 32568433
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (0.5 µg/kg/min)
Trial: 35270330
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) continued daily activities without modification
Trial: 38939389
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K Antagonist (VKA)
Trial: 38286484
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg tenecteplase
Trial: 33565715
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (4000 IU daily)
Trial: 32073316
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C (1,500 mg per day in three divided doses) from the first postoperative day
Trial: 32073316
Drug: Routine postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine postoperative medications with placebo
Trial: 35711607
Drug: Auricular plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular plaster therapy (APT)
Trial: 36262834
Drug: Sham auricular
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham auricular plaster therapy
Trial: 34139038
Drug: Vibegron 50
RxNorm normalized name: Vibegron
DrugBank: Vibegron (DB14895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vibegron 50 mg (V50)
Trial: 34139038
Drug: Vibegron 100
RxNorm normalized name: Vibegron
DrugBank: Vibegron (DB14895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vibegron 100 mg (V100)
Trial: 33022197
Drug: SKNB19 (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKNB19 (twice a day application)
Trial: 35727626
Drug: Unguided IBI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided IBI using cognitive behavior therapy
Trial: 35320361
Drug: 80 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 μg dasiglucagon
Trial: 35320361
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg dasiglucagon
Trial: 38215886
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (10 g)
Trial: 34415795
Drug: Topical lotilaner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lotilaner ophthalmic solution, 0.25%, treated bid for 42 days
Trial: 32275032
Drug: Ketorolac 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 120 mg
Trial: 32275032
Drug: Paracetamol 4
RxNorm normalized name: Paracetamol 48.2 mg/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 4 g
Trial: 36181047
Drug: XGBoost model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XGBoost model with variables related to intravenous (IV) fluid management and electrolytes
Trial: 34044245
Drug: Daily antioxidant
RxNorm normalized name: Ascorbic Acid/Selenium/Vitamin A/Vitamin E Oral Capsule, Liquid Filled [DAILY ANTIOXIDANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antioxidant supplement comprising polyphenols, omega‐3 fatty acids, vitamin E, and selenium
Trial: 32026568
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplements (LNS) during pregnancy and 6 months postpartum
Trial: 34809475
Drug: Temporary basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary basal rate and extended bolus features in addition to basal insulin modifications
Trial: 34809475
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin adjustments only
Trial: 34420200
Drug: Vitamin-containing amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-containing amino acid supplement (LGA group)
Trial: 35966733
Drug: Warm needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needle acupuncture plus Xitong Waixi lotion
Trial: 35966733
Drug: Xitong Waixi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xitong Waixi lotion
Trial: 33243443
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus EP-100 (80 mg/m2 paclitaxel intravenously plus 30 mg/m2 EP-100 intravenously)
Trial: 33243443
Drug: Paclitaxel alone
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel alone (80 mg/m2 intravenously)
Trial: 33407801
Drug: upadacitinib 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 7.5 mg QD
Trial: 37945286
Drug: upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 15 mg QD
Trial: 37945286
Drug: upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 30 mg QD
Trial: 33407801
Drug: upadacitinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib (all doses) after switching from placebo
Trial: 33407801
Drug: upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 15 mg and 30 mg
Trial: 33407801
Drug: upadacitinib 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 7.5 mg and 15 mg
Trial: 36383809
Drug: Dexmedetomidine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (bolus 0.5 mcg/kg followed by 0.7 mcg/kg/h)
Trial: 33839465
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids and potassium thiocyanate with standard treatment of SCA (test group, N = 14)
Trial: 33839465
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment only (control group, N = 7)
Trial: 33135390
Drug: Lemborexant 10
RxNorm normalized name: lemborexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 10 mg with famotidine
Trial: 34412739
Drug: Potential clinically
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential clinically significant drug-drug interactions (DDIs) detected using Lexicomp software
Trial: 32583957
Drug: Umibecestat (orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umibecestat (orally active β‐secretase inhibitor)
Trial: 32240832
Drug: Antibiotics (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (n = 85) for 7 days
Trial: 32240832
Drug: Antibiotics (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (n = 85)
Trial: 34063455
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (PD-1 and PD-L1 antibodies)
Trial: 34193480
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 0.25 mg/kg
Trial: 32962684
Drug: Generic cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic cognitive-behavioral therapy self-help in app
Trial: 33359106
Drug: Acetaminophen 500-mg
RxNorm normalized name: acetaminophen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500-mg tablet 45 minutes before reduction
Trial: 35791295
Drug: Intranasal testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal testosterone (NT) 11 mg TID
Trial: 35791295
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone cypionate (TC) 200 mg ×2 weeks
Trial: 35791295
Drug: Subcutaneous testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous testosterone pellets (TP) 800 mg
Trial: 33038531
Drug: Diuretic efficiency
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic efficiency (DE) calculated as net fluid output per 40 mg of furosemide equivalents
Trial: 34359097
Drug: Salbutamol 400
RxNorm normalized name: Salbutamol 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 400 μg
Trial: 33098800
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic blood pressure goal of less than 120 mm Hg)
Trial: 33411585
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral methotrexate at a dose of 20 mg/m2 (MTX20)
Trial: 33411585
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral methotrexate at a dose of 40 mg/m2 (MTX40)
Trial: 38174564
Drug: Immediate antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antihypertensive treatment
Trial: 34763950
Drug: HAPIBEV™ vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAPIBEV™ vaccine
Trial: 37661535
Drug: Havrix® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Havrix® vaccine
Trial: 32885352
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (HDD)
Trial: 35364022
Drug: CYD-TDV booster
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYD-TDV booster after 1 year (two-dose primary schedule)
Trial: 35364022
Drug: CYD-TDV booster
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYD-TDV booster after 2 years (two-dose primary schedule)
Trial: 34526950
Drug: Remote ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischemic conditioning (twice daily for 5 days, blood pressure cuff inflated to 20 mmHg above systolic blood pressure, up to 180 mmHg)
Trial: 32347270
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) 1 gram (830 mg of GTP) with quercetin (Q) 800 mg
Trial: 38153735
Drug: Behavioral Therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Therapy (BT)
Trial: 37619705
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acetaminophen and ibuprofen
Trial: 33486572
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of 10 g viscous fiber, 60 g white chia seeds, 1.5 g American ginseng, and 0.75 g Korean ginseng extracts
Trial: 33486572
Drug: Energy and
RxNorm normalized name: Energy And Endurance Testosterone UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy and fiber-matched control (53 g oat bran, 25 g inulin, 25 g maltodextrin, and 2.25 g wheat bran)
Trial: 33025690
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg IV acetaminophen
Trial: 33332726
Drug: Dexamethasone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.1 mg/kg and 1 mg/kg) for 10 days
Trial: 33332726
Drug: Propranolol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (30 mg/kg) as positive control
Trial: 33332726
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (10 ml/kg) as negative control
Trial: 35094120
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention (breathing exercises + manual therapy)
Trial: 34256550
Drug: 34 kcal
RxNorm normalized name: nut. therapy for PKU, no.49 2 gram-34 kcal/100 mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 34 kcal of a fructose solution daily for 5 days
Trial: 34256550
Drug: Water for
RxNorm normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water for the first 5 days followed by 34 kcal fructose solution
Trial: 32057907
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release formulations containing a model drug of BCS class III
Trial: 32965655
Drug: Cal/BD foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cal/BD foam applied twice weekly for up to 52 weeks